A discovery has been made that could change the way obesity treatment is approached and dealt with, according to a group of researchers.
The team, led by Pappachan Kolattukudy from the University of Central Florida, idenitified a new genetic mechanism that controls the way the body builds up fat called Monocyte chemotactic protein-1 induced protein (MCPIP).
He claimed the research showed that MCPIP feeds the growing fat tissue and that the mechanism could be an ideal target for medication.
"A drug that can shut down its function can prevent obesity and the major inflammatory diseases resulting from obesity including diabetes and cardiovascular diseases," he said.
The report is set to appear in the Journal of Biological Chemistry, a publication of the American Society for Biochemistry and Molecular Biology, where it will state that an estimated 300 million people will have diabetes by the year 2025.
Previously, a protein called peroxisome proliferator-activated receptor gamma was widely believed to control fat cell formation.